

SUPPLEMENT

Figure S1.

Overall mortality in the four treatment groups (placebo, fluticasone furoate, vilanterol, and combined fluticasone furoate and vilanterol) according to previous treatment use. Panel A shows those ICS alone as previous treatment use and Panel B shows those on LABD alone as previous treatment use.

Figure S2.

Risk of moderate/severe exacerbations in the four treatment groups (placebo, fluticasone furoate, vilanterol, and combined fluticasone furoate and vilanterol) according to previous treatment use. Panel A shows those ICS alone as previous treatment use and Panel B shows those on LABD alone as previous treatment use.

Figure S1A:


Subgroup: Previous ICS alone

Reduction in Risk of Dying vs. Placebo:

FF/VI 1% (-126%, 57%)

FF -46% (-211%, 32%)

VI -35% (-185%, 3%)



N alive:				
Placebo	176	163	92	34
FF 100	148	133	68	20
VI 25	169	150	83	29
FF/VI 100/25	150	130	81	28

Figure S1B:


Subgroup: Previous LABD alone

Reduction in Risk of Dying vs. Placebo:

FF/VI 5% (-61%, 44%)

FF 7% (-60%, 45%)

VI 26% (-29%, 58%)



N alive:				
Placebo	464	410	230	92
FF 100	406	368	198	77
VI 25	449	393	208	97
FF/VI 100/25	415	368	207	84

Figure S2A:

Subgroup: Previous ICS alone





Figure S2B:

Subgroup: Previous LABD alone

Reduction in Risk of mod/sev exacerbation vs. Placebo:

FF/VI 23% (2%, 39%)
FF 3% (-23%, 23%)
VI 12% (-10%, 30%)



N without exacerbation:

	0	1	2	3
Placebo	464	266	104	32
FF 100	406	239	89	25
VI 25	449	275	107	34
FF/VI 100/25	415	277	121	37